Connor, Clark & Lunn Investment Management (CC&L)’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.9M | Sell |
447,217
-150,298
| -25% | -$3.98M | 0.04% | 356 |
|
|
2025
Q1 | $14.4M | Buy |
597,515
+222,293
| +59% | +$5.37M | 0.06% | 246 |
|
|
2024
Q4 | $15.1M | Buy |
375,222
+216,873
| +137% | +$8.73M | 0.07% | 221 |
|
|
2024
Q3 | $10M | Buy |
158,349
+108,581
| +218% | +$6.87M | 0.05% | 276 |
|
|
2024
Q2 | $2.64M | Buy |
+49,768
| New | +$2.64M | 0.01% | 583 |
|
|
2023
Q4 | – | Sell |
-76,360
| Closed | -$845K | – | 1573 |
|
|
2023
Q3 | $845K | Sell |
76,360
-121,051
| -61% | -$1.34M | ﹤0.01% | 870 |
|
|
2023
Q2 | $3.2M | Buy |
197,411
+106,985
| +118% | +$1.73M | 0.02% | 486 |
|
|
2023
Q1 | $1.51M | Buy |
90,426
+2,180
| +2% | +$36.3K | 0.01% | 624 |
|
|
2022
Q4 | $830K | Sell |
88,246
-171,641
| -66% | -$1.61M | ﹤0.01% | 753 |
|
|
2022
Q3 | $707K | Buy |
259,887
+37,025
| +17% | +$101K | ﹤0.01% | 733 |
|
|
2022
Q2 | $644K | Buy |
222,862
+104,156
| +88% | +$301K | ﹤0.01% | 722 |
|
|
2022
Q1 | $356K | Buy |
118,706
+79,507
| +203% | +$238K | ﹤0.01% | 844 |
|
|
2021
Q4 | $180K | Buy |
39,199
+15,249
| +64% | +$70K | ﹤0.01% | 991 |
|
|
2021
Q3 | $150K | Buy |
23,950
+9,939
| +71% | +$62.2K | ﹤0.01% | 962 |
|
|
2021
Q2 | $84K | Buy |
+14,011
| New | +$84K | ﹤0.01% | 947 |
|